Does PRRT with standard activities of (177)Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-[DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 mCi) per course bound to 180 to 300 μg of the peptide. While this single activity may lead to suboptimal radiation doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabet, Amir, Nagarajah, James, Dogan, Ahmet Semih, Biersack, Hans-Jürgen, Sabet, Amin, Guhlke, Stefan, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877953/
https://www.ncbi.nlm.nih.gov/pubmed/24369053
http://dx.doi.org/10.1186/2191-219X-3-82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877953/
https://www.ncbi.nlm.nih.gov/pubmed/24369053
http://dx.doi.org/10.1186/2191-219X-3-82

Ejemplares similares